Tang YK, Xu Z, Ye ZM, Li SR, et al. Cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of patients with metastatic or recurrent nasopharyngeal carcinoma in China. Head Neck 2023 Oct 17. doi: 10.1002/hed.27544.
PMID: 37846175